Ditchcarbon
  • Contact
  1. Organizations
  2. Organon
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated a month ago

Organon

Company website

Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions. With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.

DitchCarbon Score

How does Organon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

34

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

32

Industry Benchmark

Organon's score of 34 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.

56%

Let us know if this data was useful to you

Organon's reported carbon emissions

In 2023, Organon reported total carbon emissions of approximately 7,200,000 kg CO2e from Scope 1 and Scope 2 sources, with Scope 1 emissions at about 2,272,000 kg CO2e and Scope 2 emissions at approximately 5,557,000 kg CO2e (market-based). Additionally, Scope 3 emissions were significant, with business travel contributing about 415,000 kg CO2e, employee commute at approximately 830,000 kg CO2e, and waste generated in operations at around 130,000 kg CO2e. For 2022, Organon’s emissions were approximately 11,220,000 kg CO2e for Scope 1 and about 5,677,000 kg CO2e for Scope 2 (market-based), while Scope 3 emissions totalled around 6,000,000 kg CO2e, with upstream transportation and distribution accounting for about 1,750,000 kg CO2e. Organon has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 GHG emissions by more than 25% from 2020 levels by 2025. This target reflects a commitment to sustainability and aligns with industry standards for climate action. The company’s emissions data is sourced directly from Organon & Co., with no cascaded data from a parent organization. Overall, Organon is actively working towards reducing its carbon footprint while maintaining transparency in its emissions reporting.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

202020212022
Scope 1
30,521,000
00,000,000
00,000,000
Scope 2
32,908,000
00,000,000
00,000,000
Scope 3
-
-
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Organon's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Organon is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Organon is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Almirall Hermal GmbH

DE
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Regeneron

US
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Mayne Pharma

AU
•
Pharmaceutical Preparation Manufacturing
Updated 24 days ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 5 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251008.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy